{"brief_title": "Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes", "brief_summary": "This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus\u00ae injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.", "condition": "Type 2 Diabetes Mellitus", "intervention_type": "Drug", "intervention_name": "Metformin", "description": "Patients usual dosage", "arm_group_label": "Insulin Glargine Arm", "other_name": "Lantus", "criteria": "Inclusion Criteria: - Diagnosis of type 2 diabetes, but otherwise healthy - HbA1c between 6.6% and 9.5%, inclusive. - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive. - Treated with a stable dose of metformin for at least 2 months prior to screening. Exclusion Criteria: - Patients previously in a study using exenatide. - Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening). - Treated with insulin within 3 months of screening.", "gender": "All", "minimum_age": "30 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00097500.xml"}